A phase I, open label, clinical study to assess the safety and immunogenicity of indigenously developed liquid (DTwP-HepB-IPV-Hib) hexavalent combination vaccine in healthy toddlers aged 16–24 months
Authors:
Open Access
- 22 November 2022
- journal article
- research article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 18 (6) , 2146435
Abstract
This first in human study was designed as an open label clinical trial to assess the safety and immunogenicity of SIIPL DTwP-HepB-IPV-Hib (Hexavalent) combination vaccine in healthy toddlers, aged 16–24 months. A total of 24 healthy toddlers were administered a 0.5 ml single dose of SIIPL DTwP-HepB-IPV-Hib vaccine intramuscularly, and followed for 28 days for safety outcomes viz. immediate, solicited, unsolicited and serious adverse events. Blood samples were collected immediately prior to and 28 days after vaccination to assess the immunogenicity. Twenty four completed the study in compliance with the study protocol. None of the participants experienced any immediate or any serious adverse event. In terms of the frequency and intensity, the adverse events were comparable to DTwP-based combination vaccines. The vaccine elicited a strong booster response as demonstrated by a large increase in antibodies against all vaccine antigens. One month post booster vaccination seroprotection for diphtheria, tetanus, Hepatitis B, Haemophilus influenzae type b and polio virus type 1 and 3 was 100%. The percentage sero-response for pertussis was 75%. Four-fold increase in antibody concentration for pertussis was achieved in 87.5% subjects. Indigenously developed DTwP-HepB-IPV-Hib vaccine by Serum Institute of India Pvt. Ltd. was found to be safe, well tolerated and showed a robust immune response in toddlers. It was concluded that this vaccine should be assessed in the next phases of clinical development in the target population. Clinical Trial Registration – CTRI/2018/10/015875.Keywords
Funding Information
- Serum Institute of India Pvt. Ltd
This publication has 11 references indexed in Scilit:
- Highly affordable vaccines are critical for our continued efforts to reduce global childhood mortalityHuman Vaccines & Immunotherapeutics, 2019
- Guidance for Assessment of Poliovirus Vaccination Status and Vaccination of Children Who Have Received Poliovirus Vaccine Outside the United StatesMMWR. Morbidity and Mortality Weekly Report, 2017
- Safety, immune lot-to-lot consistency and non-inferiority of a fully liquid pentavalent DTwp-HepB-Hib vaccine in healthy Indian toddlers and infantsHuman Vaccines & Immunotherapeutics, 2015
- Hexavalent IPV-based combination vaccines for public-sector markets of low-resource countriesHuman Vaccines & Immunotherapeutics, 2013
- The final stages of the global eradication of poliomyelitisPhilosophical Transactions of the Royal Society B: Biological Sciences, 2013
- Antibody persistence of two pentavalent DTwP–HB–Hib vaccines to the age of 15–18 months, and response to the booster dose of quadrivalent DTwP–Hib vaccineVaccine, 2013
- A randomized, dose-ranging assessment of the immunogenicity and safety of a booster dose of a combined diphtheria-tetanus-whole cell pertussis-hepatitis B-inactivated poliovirus-Hemophilus influenzaetype b (DTPw-HBV-IPV/Hib) vaccine vs. co-administration of DTPw-HBV/Hib and IPV vaccines in 12 to 24 months old Filipino toddlersHuman Vaccines & Immunotherapeutics, 2012
- Immunogenicity and safety of an indigenously manufactured reconstituted pentavalent (DTwP-HBV+Hib) vaccine in comparison with a foreign competitor following primary and booster immunization in Indian childrenHuman Vaccines, 2011
- Combination VaccinesJournal of Global Infectious Diseases, 2011
- State of the Globe: Tracking Tuberculosis is the Test of TimeJournal of Global Infectious Diseases, 2011